SEC Comment Letter for Summit Therapeutics Inc. (SMMT) (CIK 0001599298) (SMMT) — Jan 21, 2025

Summit Therapeutics Inc. (SMMT) (CIK 0001599298)
Date: Jan. 21, 2025 · CIK: 0001599298 · Accession: 0000000000-25-000593

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-36866

Date

January 21, 2025

Author

Robert Duggan

Form

UPLOAD

Company

Summit Therapeutics Inc. (SMMT) (CIK 0001599298)

Letter

January 21, 2025 Robert Duggan Chairman and Co-Chief Executive Officer Summit Therapeutics, Inc. 601 Brickell Key Drive, Suite 1000 Miami, FL 33131 Re:Summit Therapeutics, Inc. Form 10-K for Fiscal Year Ended December 31, 2023 File No. 001-36866 Dear Robert Duggan: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

January 21, 2025
Robert Duggan
Chairman and Co-Chief Executive Officer
Summit Therapeutics, Inc.
601 Brickell Key Drive, Suite 1000
Miami, FL 33131
Re:Summit Therapeutics, Inc.
Form 10-K for Fiscal Year Ended December 31, 2023
File No. 001-36866
Dear Robert Duggan:
            We have completed our review of your filing. We remind you that the company and
its management are responsible for the accuracy and adequacy of their disclosures,
notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io